Delving into the Latest Updates on Vicriviroc with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

SCH-D, Schering-D, Vicriviroc maleate (USAN)

+ [4]

Target

CCR5

Mechanism

CCR5 antagonists(C-C chemokine receptor type 5 antagonists), Virus internalization inhibitors

Therapeutic Areas

Immune System DiseasesInfectious DiseasesUrogenital Diseases+ [2]

Active Indication-

Inactive Indication

Acquired Immunodeficiency SyndromeColorectal CancerHIV Infections

Originator Organization

Merck & Co., Inc.

Active Organization-

Inactive Organization

Merck GmbH

Merck Sharp & Dohme Corp.

Merck & Co., Inc.

Drug Highest PhaseDiscontinuedPhase 3

First Approval Date-

Regulation-

Login to view timeline

Structure

Molecular FormulaC28H38F3N5O2

InChIKeyCNPVJJQCETWNEU-CYFREDJKSA-N

CAS Registry306296-47-9

Pembrolizumab, a monoclonal antibody against PD-1, has shown limited efficacy in patients with microsatellite stable or mismatch repair proficient (MSS/pMMR) metastatic colorectal cancer (CRC). We evaluated vicriviroc (small-molecule C-C motif chemokine ligand 5 antagonist) plus pembrolizumab in patients with advanced or metastatic MSS/pMMR CRC.

PATIENTS AND METHODS:

This open-label, phase 2 trial (NCT03631407) enrolled adults with histologically confirmed, locally advanced, unresectable or metastatic CRC that was MSS per local assessment. All patients had received previous treatment with standard therapies. Patients were randomized 1:1 to vicriviroc 150 mg orally once daily plus pembrolizumab 200 mg intravenously every 3 weeks or vicriviroc 250 mg orally once daily plus pembrolizumab 200 mg intravenously every 3 weeks for up to 35 cycles (2 years). Primary endpoints were the objective response rate (ORR) as assessed by the investigator per RECIST v1.1, dose-limiting toxicities (DLTs), adverse events (AEs), and discontinuations due to AEs.

RESULTS:

Forty patients were enrolled and treated. ORR was 5% (95% CI, 0.1%-24.9%) in both treatment groups. There were no complete responses; 1 patient in each treatment group experienced a partial response. No patient in the vicriviroc 150 mg plus pembrolizumab group experienced a DLT. Two patients in the vicriviroc 250 mg plus pembrolizumab group experienced DLTs (1 grade 4 encephalopathy and 1 grade 4 pneumonitis).

CONCLUSION:

The combination of vicriviroc at doses of 150 or 250 mg plus pembrolizumab 200 mg showed limited antitumor activity in patients with advanced or metastatic MSS/pMMR CRC. Toxicity with the combination was manageable.

08 Sep 2023·Cells

The Role and Therapeutic Targeting of CCR5 in Breast Cancer.

Review

Author: Halama, Niels ; Alaziz, Mustafa ; Mahal, Amanpreet S ; Pestell, Richard G ; Jaeger, Dirk ; Hamid, Rasha ; Ashton, Anthony W ; Jiao, Xuanmao

The G-protein-coupled receptor C-C chemokine receptor 5 (CCR5) functions as a co-receptor for the entry of HIV into immune cells. CCR5 binds promiscuously to a diverse array of ligands initiating cell signaling that includes guided migration. Although well known to be expressed on immune cells, recent studies have shown the induction of CCR5 on the surface of breast cancer epithelial cells. The function of CCR5 on breast cancer epithelial cells includes the induction of aberrant cell survival signaling and tropism towards chemo attractants. As CCR5 is not expressed on normal epithelium, the receptor provides a potential useful target for therapy. Inhibitors of CCR5 (CCR5i), either small molecules (maraviroc, vicriviroc) or humanized monoclonal antibodies (leronlimab) have shown anti-tumor and anti-metastatic properties in preclinical studies. In early clinical studies, reviewed herein, CCR5i have shown promising results and evidence for effects on both the tumor and the anti-tumor immune response. Current clinical studies have therefore included combination therapy approaches with checkpoint inhibitors.

13 Apr 2020·ACS biomaterials science & engineeringQ3 · ENGINEERING & TECHNOLOGY

Mesoporous Hydroxyapatite Nanoparticles Mediate the Release and Bioactivity of BMP-2 for Enhanced Bone Regeneration

Q3 · ENGINEERING & TECHNOLOGY

Article

Author: Zhao, Yong ; Chen, Jiang ; Qiu, Yubei ; Guo, Weizhong ; Su, Jiehua ; Xu, Xiaodong

Efficient delivery of bone morphogenetic protein-2 (BMP-2) with desirable bioactivity is still a great challenge in the field of bone regeneration. In this study, a silk fibroin/chitosan scaffold incorporated with BMP-2-loaded mesoporous hydroxyapatite nanoparticles (mHANPs) was prepared (SCH-L). BMP-2 was preloaded onto mHANPs with a high surface area before mixing with a silk fibroin/chitosan composite. Bare (without BMP-2) silk fibroin/chitosan/mHANP (SCH) scaffolds and SCH scaffolds with directly absorbed BMP-2 (SCH-D) were investigated in parallel for comparison. In vitro release kinetics indicated that BMP-2 released from the SCH-L scaffold showed a significantly lower initial burst release, followed by a more sustained release over time than the SCH-D scaffold. In vitro cell viability, osteogenic differentiation of bone marrow mesenchymal stem cells (BMSCs), and the in vivo osteogenic effect of scaffolds in a rat calvarial defect were evaluated. The results showed that compared with bare SCH and SCH-D scaffolds, the SCH-L scaffold significantly promoted the osteogenic differentiation of BMSCs in vitro and induced more pronounced bone formation in vivo. Further studies demonstrated that the mHANP-mediated satisfactory conformational change and sustained release benefited the protection of the released BMP-2 bioactivity, as confirmed by alkaline phosphatase (ALP) activity and a mineralization deposition assay. More importantly, the interaction of BMP-2/mHANPs enhanced the binding ability of BMP-2 to cellular receptors, thereby maintaining its biological activity in osteogenic differentiation and osteoinductivity well, which contributed to the markedly promoted in vitro and in vivo osteogenic efficacy of the SCH-L scaffold. Taken together, these results provide strong evidence that mHANPs represent an attractive carrier for binding BMP-2 to scaffolds. The SCH-L scaffold shows promising potential for bone tissue regeneration applications.

1

News (Medical) associated with Vicriviroc

08 Feb 2023

·www.biospace.com

Infectious disease specialist Dr. Regis A. Vilchez is appointed CMO of MicuRx Pharmaceuticals, Inc.

SHANGHAI, Feb. 8, 2023 /PRNewswire/ -- Shanghai MicuRx Pharmaceutical Co., Ltd. ("MicuRx," 688373) announced recently that it has appointed Regis A. Vilchez, MD, PhD, an experienced R&D biopharmaceutical executive and infectious disease expert, as Chief Medical Officer of its American subsidiary, MicuRx Pharmaceuticals, Inc. He oversees new drug development programs and clinical activities in the United States, Europe and other regions. Dr. Vilchez earned an M.D. from the Universidad Autónoma de Centro América in Costa Rica and a Ph.D. from Baylor College of Medicine in Houston, Texas, the United States. He completed an internal medicine residency at Robert Wood Johnson Medical School, a clinical infectious diseases fellowship at the University of Pittsburgh, and a molecular virology fellowship at Baylor College of Medicine. Prior to entering the biopharmaceutical industry, Dr. Vilchez was full time faculty in the Departments of Medicine and Molecular Virology & Microbiology at Baylor College of Medicine. Dr. Vilchez has served in multiple R&D roles at Boehringer Ingelheim, Merck, Roche, Abbott/AbbVie, Mallinckrodt Pharmaceuticals and other smaller biotechnology companies. In those roles, Dr. Vilchez has been a key contributor to the global development of new therapies such as Vicriviroc, Victrelis, Viekirax, Technivie, Ocaliva, Terlivaz, and StrataGraft. Dr. Vilchez has co-authored more than 100 peer-reviewed scientific publications in high impact biomedical journals such as the New England Journal of Medicine, The Lancet, and Clinical Microbiology Reviews. The leadership of Dr. Vilchez will enhance MicuRx's global R&D programs and clinical activities. MicuRx is rapidly expanding its business and assembling an international expert team with extensive experience and an innovative spirit to develop a robust global R&D organization. Moving forward, MicuRx will remain focused on advancing its anti-infective product pipeline, and provide more effective and safer treatment options for patients around the world. View original content to download multimedia: SOURCE MicuRx Pharmaceuticals Company Codes: Shanghai:688373, Shanghai:688373.SS

Executive Change

100 Deals associated with Vicriviroc

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D06297	Vicriviroc	-	DB06652

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
HIV Infections	Phase 3	US	Merck & Co., Inc.	05 May 2010
Acquired Immunodeficiency Syndrome	Phase 3	-	Merck Sharp & Dohme Corp.	01 Sep 2005
Colorectal Cancer	Phase 2	US	Merck & Co., Inc.	24 Sep 2018
Colorectal Cancer	Phase 2	CA	Merck Sharp & Dohme Corp.	24 Sep 2018

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT00243230 (MK-7690-020 \| VICTOR-E1 \| P03672, CTgov)	Phase 2	HIV Infections	116	Vicriviroc (Double-Blind Period - Vicriviroc 30 mg Plus an ART Regimen)	ersrublzug(ojhyhboyng) = bubktgoahg yqjmabnacf (uggxurqzkg, mttnfogygv - uzcnclpnal) View more	-	08 Jun 2021
				Vicriviroc (Double-Blind Period - Vicriviroc 20 mg Plus an ART Regimen)	ersrublzug(ojhyhboyng) = gblfvwmajk yqjmabnacf (uggxurqzkg, nahvypwkpe - roatmikgav) View more
NCT00686829 (A5211 \| P04100, CTgov)	Phase 2	HIV Infections	79	Vicriviroc maleate	xvikclkzzg(edmbepoccq) = fgkxkuyitr mxjohcnoqw (ncdrjcpohn, rafrtgnilg - xqdoimfekx) View more	-	03 Dec 2020
NCT00474370 \| NCT00523211 (VICTOR-E3, VICTOR-E4, Pubmed \| J Infect)	Phase 3	HIV Infections	-	Vicriviroc 30 mg QD	tyffeqkdat(zioixrxrrz) = izujpzbxri mtgvxresll (yqxyyvmmqx ) View more	Negative	01 Oct 2012
				Placebo	tyffeqkdat(zioixrxrrz) = upfhxefqng mtgvxresll (yqxyyvmmqx ) View more
NCT00686829 (A5211, Pubmed \| HIV Clin Trials)	Phase 2	Peripheral Nervous System Diseases	118	Vicriviroc (pooled doses)	ifdxzqbfpc(fuxrfynlqp): OR = 1.52 (95% CI, 0.59 - 3.9), P-Value = 0.39	Negative	28 Feb 2010
				Placebo
NCT00243230 (Pubmed \| J Infect Dis)	Phase 2	CCR5-tropic HIV	-	Vicriviroc 30 mg	qppxclblfn(yrhroawcbc) = jgmjynuzos shurqfkihy (ngywbtyqki )	-	15 Feb 2010
				Vicriviroc 20 mg	qppxclblfn(yrhroawcbc) = tfdelnomni shurqfkihy (ngywbtyqki )
ACTG 5211 (IAS2008)	Not Applicable	-	79	Vicriviroc 15 mg	vfmbrxyvur(lqgtuleaam) = Hodgkin´s disease (previously reported in Gulick, JID 2007) vebheotmhh (wuytpdtdbx ) View more	-	01 Jan 2008
NCT00243230 (VICTOR-E1, IAS2007)	Not Applicable	-	116	Vicriviroc 20mg	jhtzomexjr(twwhujyjeh) = xctslbegvt dkhdurbcgq (futkehpnqh ) View more	-	01 Jan 2007
				Vicriviroc 30mg	jhtzomexjr(twwhujyjeh) = wkcnkjysni dkhdurbcgq (futkehpnqh ) View more
ACTG 5211 (IAS2007)	Not Applicable	HIV Infections	118	Vicriviroc 10 mg	ckjvnmxmhu(mggcfrtuiw) = were similar across arms bdulwgjhkg (evhnecdgyr ) View more	-	01 Jan 2007
				Vicriviroc 15 mg
NCT00243230 (VICTOR-E1, IAS2007)	Not Applicable	HIV Infections	116	vicriviroc 20mg	xiajejpxnq(ciwvhhhikh) = jhbqjleevd sjwxpklwgz (dxpavihyqv ) View more	-	01 Jan 2007